Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1: GU tumours, non-prostate

1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials


11 Sep 2022


Mini Oral session 1: GU tumours, non-prostate


Tumour Site

Urothelial Cancer


Tim Smith


Annals of Oncology (2022) 33 (suppl_7): S785-S807. 10.1016/annonc/annonc1080


T.A.D. Smith1, C.M. West1, B. Lane1, J. irlam-jones1, E. More1, H. Mistry1, P.J. Hoskin2, S.A. Hussain3, E. Hall4, N. Porta4, R.A. Huddart5, N.D. James6, A. Choudhury2

Author affiliations

  • 1 Division Of Cancer Sciences, The University of Manchester, M20 4GJ - MANCHESTER/GB
  • 2 Division Of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 3 Department Of Biostatistics 1st Floor, University of Sheffield Medical School, S10 2RX - Sheffield/GB
  • 4 Clinical Trials And Statistics Unit, ICR - Institute of Cancer Research, SM2 5PT - Sutton Surrey/GB
  • 5 Radiotherapy And Imaging Dept., Royal Marsden Hospital Institute of Cancer Research, SM2 5NG - Sutton/GB
  • 6 Prostate And Bladder Cancer Research Department, ICR - Institute of Cancer Research, SW7 3RP - London/GB


Login to access the resources on OncologyPRO.

Abstract 1734MO


Radical treatment for muscle-invasive bladder cancer (MIBC) involves radiotherapy with radiosensitiser or cystectomy currently selected subjectively (patient/clinician preference). The West 24-gene bladder cancer hypoxia signature predicted benefit from hypoxia-modifying radiosensitisation (carbogen+nicotinamide, CON) in BCON trial. The BC2001 trial showed combining chemotherapy (5-FU, mitomycin-C) with radiotherapy (RT) improves loco-regional progression free survival. Both BCON and BC2001 allowed conventional (62Gy/32 fractions) or hypofractionated (55Gy/20 fractions) RT. We tested two hypotheses: (1) our hypoxia signature does not predict benefit from concurrent chemotherapy; and (2) accelerated treatment reduces reoxygenation and is less favourable for patients with hypoxic tumours.


Pre-treatment biopsy samples were obtained from 312 patients from BC2001. RNA was extracted and full transcriptomic data generated using Affymetrix Clariom S arrays. Patients were stratified using the cohort median of the median expression of 24-signature genes hypoxia score into hypoxia-high and -low groups. Data for BCON (n=151) were available from a published study.


Hypoxia score was prognostic for overall survival in the combined BC2001 cohort in univariable and multivariable (HR=1.29; 95% CI 0.97-1.71; p=0.075) analyses with no interaction between hypoxia score and treatment arm (p=0.92) Patients with hypoxic tumours had a poorer prognosis following hypofractionated compared with conventional fractionation in both BC2001 (n=298, HR 1.80 95% CI 1.08-2.91; p=0.023) and the BCON RT only arm (n=75; HR 14.2; 95% CI 1.7-119; p=0.015). CON abrogated the detrimental effect of hypoxia with hypofractionated RT.


Hypoxic MIBC has a poor prognosis and exhibits fraction sensitivity, which is mitigated with hypoxia modification. Use of hypoxia score to personalise treatment needs testing in a biomarker-stratified trial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.